Skip to main content

Table 1 B-cell targeting biologics in clinical development

From: B-cell targeted therapeutics in clinical development

Target Therapeutic Format Mechanism Indication Clinical stageaa
CD20 Rituximab Chimeric Depletion RA Approved
   IgG1 ADCC, CDC Pemphigus Phase 3
     AIHA Phase 3
     ITP Phase 3 (newly diagnosed)
     ITP Phase 2
     Acute IPF Phase 1/2 (with plasma exchange)
     AIR Phase 1
  Ofatumumab Humanized Depletion RA Phase 3
   IgG1 ADCC, CDC RRMS Phase 2
     RRMS Phase 2 (subcutaneously)
  Ocrelizumab Humanized Depletion RRMS Phase 3
   IgG1 ADCC, CDC PPMS Phase 3
     SLE Phase 3
  Veltuzumab Humanized Depletion RA Phase 2
   IgG1 ADCC, CDC ITP Phase 1/2
CD19 MEDI-551 Humanized Depletion SSc Phase 1
   IgG1 afucosylated ADCC RRMS Phase 1
CD22 Epratuzumab Humanized Partial depletion SLE Phase 3
   IgG1 B-cell activation  
BAFF Belimumab Human Ligand neutral SLE Approved
   IgG1 Survival SLE Phase 3 (subcutaneously)
     ITP Phase 2
     MG Phase 2
  Tabalumab Human Ligand neutral SLE Phase 3 (subcutaneously)
IgG4    Survival RA Phase 2
  Blisibimod Peptibody Ligand neutral SLE Phase 3
     ITP Phase 2/3
BAFF/APRIL Atacicept Receptor Ligand neutral SLE Phase 2/3
   Fc fusion Survival   
CD40L CDP7657 Pegylated Co-stimulation SLE Phase 1
   Fab Blockade   
B7RP1 AMG-557 Human Co-stimulation SCLE Phase 1
   IgG Blockade Psoriasis Phase 1
     SLE Phase 1
ICOS MEDI-570 Human Depletion SLE Phase 1
   IgG1 afucosylated ADCC   
IL-21 NN8828 Humanized Ligand neutral RA Phase 1
  1. ADCC, antibody-dependent cellular cytotoxicity; AIHA, autoimmune hemolytic anemia; AIR, autoimmune retinopathy; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; CD40L, CD40 ligand; CDC, complement-dependent cytotoxicity; IPF, idiopathic pulmonary fibrosis; ITP, idiopathic thrombocytopenia purpura; MG, myasthenia gravis; PPMS, primary progressive multiple sclerosis; RA, rheumatoid arthritis; RRMS, relapsing remitting multiple sclerosis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; SSLE, subacute cutaneous lupus erythematosus. aSource for clinical trial status: (as of February 2013).